Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
28°
Light Snow
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
68.36
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
51
52
Next >
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
April 18, 2024
Via
AB Newswire
Topics
Economy
Exposures
Interest Rates
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
April 17, 2024
Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300...
Via
Benzinga
AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows
April 16, 2024
AstraZeneca's updated data from TOPAZ-1 Phase 3 trial of Imfinzi (durvalumab) in advanced biliary tract cancer patients. Unveiling long-term survival benefits and significant overall survival...
Via
Benzinga
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
April 16, 2024
From
AstraZeneca
Via
Business Wire
A Closer Look at AstraZeneca's Options Market Dynamics
April 03, 2024
Via
Benzinga
3 Pharma Stocks That Are Money-Printing Machines in 2024
April 15, 2024
The economy, and pharma industry, are projected to grow massively. You should invest in these top three pharma stocks.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
4 Exceptional Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
April 14, 2024
Amazing deals can still be found by opportunistic investors, even with the Nasdaq Composite reaching new heights.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
April 12, 2024
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee found no conclusive evidence linking GLP-1 receptor agonists to suicidal or self-injurious thoughts. Following thorough...
Via
Benzinga
Exposures
Product Safety
Biotech Innovations Paving the Way in Breast Cancer Fight
April 11, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Product Safety
AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO's Pay Package Boost
April 11, 2024
AstraZeneca boosts its 2024 dividend to $3.10/share, reflecting confidence in performance. Shareholder concerns addressed as CEO compensation proposal approaches vote. Recent acquisitions and FDA...
Via
Benzinga
Exposures
Product Safety
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
April 11, 2024
From
AstraZeneca
Via
Business Wire
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
April 08, 2024
FDA approves Daiichi Sankyo's and AstraZeneca's Enhertu for unresectable or metastatic HER2+ solid tumors. Accelerated approval based on ORR and DOR. Boxed warnings for ILD/pneumonitis and embryo-fetal...
Via
Benzinga
Exposures
Product Safety
US Manufacturing Hits 18-Month High, China's Growth Could Trigger Deflation And More: Economics Weekly Roundup
April 07, 2024
This week's top stories highlight significant developments, including the U.S. manufacturing sector reaching an 18-month high, potential deflation from China's manufacturing growth, a robust U.S. labor...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
April 05, 2024
From
Daiichi Sankyo
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
April 05, 2024
From
AstraZeneca
Via
Business Wire
New Hope for Aggressive Lung Cancer: AstraZeneca's Imfinzi Shows Promising Results in Phase 3 Trial
April 05, 2024
High-level results of AstraZeneca's ADRIATIC Phase 3 trial on Imfinzi monotherapy & Imfinzi plus Imjudo for limited-stage small cell lung cancer. Statistically significant OS & PFS improvement shown...
Via
Benzinga
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
April 05, 2024
From
AstraZeneca
Via
Business Wire
AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race
April 02, 2024
AstraZeneca's CEO Pascal Soriot celebrates hitting a $45 billion sales target set a decade ago despite initial skepticism. Investor confidence remains a challenge amid stagnant shares and concerns over...
Via
Benzinga
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
April 02, 2024
From
AstraZeneca
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN)
April 01, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH
April 01, 2024
From
Alexion
Via
Business Wire
7 Blue-Chip Stocks That Will Outperform the Dow in the 5 Five Years
March 28, 2024
These are the blue-chip stocks to outperform Dow in the next five years and represents companies with growth and cash flow visibility.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
Bull Market Buys: 3 Dividend Stocks to Own for the Long Run
March 28, 2024
Invest in stability, dividends, and growth with these three accomplished real estate operators.
Via
The Motley Fool
What's Going On European Pharma Giant AstraZeneca Stock On Wednesday?
March 27, 2024
Japan approves AstraZeneca & Sanofi's Beyfortus for respiratory syncytial virus in neonates, infants, & children. Also, Truqap receives approval for unresectable or recurrent breast cancer. AstraZeneca...
Via
Benzinga
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave
March 26, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)
March 25, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
ULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)
March 25, 2024
From
Alexion
Via
Business Wire
Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum
March 22, 2024
Via
AB Newswire
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
EXCLUSIVE: 2024 Witnesses Increase In Biotech Initial Public Offerings
March 21, 2024
Dr. Laura Chico, Senior VP at Wedbush, is optimistic about 2024 biotech IPO market and M&A trends. Election year may affect performance.
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
After Failed Prostate Cancer Study Merck's Keytruda Combination Therapy Flunks In Late-Stage Lung Cancer Study
March 21, 2024
Merck's latest findings from the KEYLYNK-006 trial on Keytruda and Lynparza combination therapy for metastatic non-small cell lung cancer reveal outcomes on survival and progression.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
51
52
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.